108 related articles for article (PubMed ID: 32466878)
1. Apalutamide in combination with autophagy inhibitors improves treatment effects in prostate cancer cells.
Eberli D; Kranzbühler B; Mortezavi A; Sulser T; Salemi S
Urol Oncol; 2020 Aug; 38(8):683.e19-683.e26. PubMed ID: 32466878
[TBL] [Abstract][Full Text] [Related]
2. Combined N-terminal androgen receptor and autophagy inhibition increases the antitumor effect in enzalutamide sensitive and enzalutamide resistant prostate cancer cells.
Kranzbühler B; Salemi S; Mortezavi A; Sulser T; Eberli D
Prostate; 2019 Feb; 79(2):206-214. PubMed ID: 30345525
[TBL] [Abstract][Full Text] [Related]
3. Apalutamide and autophagy inhibition in a xenograft mouse model of human prostate cancer.
Eberli D; Kranzbühler B; Prause L; Baumgartner V; Preda S; Sousa R; Lehner F; Salemi S
J Cancer Res Clin Oncol; 2022 Dec; 148(12):3351-3360. PubMed ID: 35751683
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of autophagy significantly increases the antitumor effect of Abiraterone in prostate cancer.
Mortezavi A; Salemi S; Kranzbühler B; Gross O; Sulser T; Simon HU; Eberli D
World J Urol; 2019 Feb; 37(2):351-358. PubMed ID: 29951789
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the effect of the antiandrogen apalutamide (ARN-509) versus bicalutamide on the androgen receptor pathway in prostate cancer cell lines.
Koukourakis MI; Kakouratos C; Kalamida D; Mitrakas A; Pouliliou S; Xanthopoulou E; Papadopoulou E; Fasoulaki V; Giatromanolaki A
Anticancer Drugs; 2018 Apr; 29(4):323-333. PubMed ID: 29381490
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Autophagy Improves the Efficacy of Abiraterone for the Treatment of Prostate Cancer.
Ma X; Zou L; Li X; Chen Z; Lin Z; Wu X
Cancer Biother Radiopharm; 2019 Apr; 34(3):181-188. PubMed ID: 30855185
[TBL] [Abstract][Full Text] [Related]
7. Androgen deprivation and androgen receptor competition by bicalutamide induce autophagy of hormone-resistant prostate cancer cells and confer resistance to apoptosis.
Boutin B; Tajeddine N; Vandersmissen P; Zanou N; Van Schoor M; Mondin L; Courtoy PJ; Tombal B; Gailly P
Prostate; 2013 Jul; 73(10):1090-102. PubMed ID: 23532738
[TBL] [Abstract][Full Text] [Related]
8. Autophagy Induction by α-Santalol in Human Prostate Cancer Cells.
Walters C; Reed M; Bartholomew S; Bommareddy A
Anticancer Res; 2021 Mar; 41(3):1197-1202. PubMed ID: 33788710
[TBL] [Abstract][Full Text] [Related]
9. Apalutamide: the established and emerging roles in the treatment of advanced prostate cancer.
Dellis AE; Papatsoris AG
Expert Opin Investig Drugs; 2018 Jun; 27(6):553-559. PubMed ID: 29856649
[TBL] [Abstract][Full Text] [Related]
10. Blocked autophagy using lysosomotropic agents sensitizes resistant prostate tumor cells to the novel Akt inhibitor AZD5363.
Lamoureux F; Thomas C; Crafter C; Kumano M; Zhang F; Davies BR; Gleave ME; Zoubeidi A
Clin Cancer Res; 2013 Feb; 19(4):833-44. PubMed ID: 23258740
[TBL] [Abstract][Full Text] [Related]
11. The development of apalutamide for the treatment of prostate cancer.
Isaacsson Velho P; Tofani Sant' Anna P; Pereira da Silva RF; Dal Ponte Ferreira R; Venero FC
Expert Opin Drug Discov; 2021 Mar; 16(3):217-226. PubMed ID: 33003959
[TBL] [Abstract][Full Text] [Related]
12. CAPN2 promotes apalutamide resistance in metastatic hormone-sensitive prostate cancer by activating protective autophagy.
Qi Z; Bai X; Wu L; Zhang P; Guo Z; Yu Y
J Transl Med; 2024 Jun; 22(1):538. PubMed ID: 38844946
[TBL] [Abstract][Full Text] [Related]
13. Dual inhibition of autophagy and the AKT pathway in prostate cancer.
Lamoureux F; Zoubeidi A
Autophagy; 2013 Jul; 9(7):1119-20. PubMed ID: 23670050
[TBL] [Abstract][Full Text] [Related]
14. mTOR is a fine tuning molecule in CDK inhibitors-induced distinct cell death mechanisms via PI3K/AKT/mTOR signaling axis in prostate cancer cells.
Berrak O; Arisan ED; Obakan-Yerlikaya P; Coker-Gürkan A; Palavan-Unsal N
Apoptosis; 2016 Oct; 21(10):1158-78. PubMed ID: 27484210
[TBL] [Abstract][Full Text] [Related]
15. CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells.
Ishikura N; Kawata H; Nishimoto A; Nakamura R; Tsunenari T; Watanabe M; Tachibana K; Shiraishi T; Yoshino H; Honma A; Emura T; Ohta M; Nakagawa T; Houjo T; Corey E; Vessella RL; Aoki Y; Sato H
Int J Oncol; 2015 Apr; 46(4):1560-72. PubMed ID: 25634071
[TBL] [Abstract][Full Text] [Related]
16. Paradoxical effects of the autophagy inhibitor 3-methyladenine on docetaxel-induced toxicity in PC-3 and LNCaP prostate cancer cells.
Pickard RD; Spencer BH; McFarland AJ; Bernaitis N; Davey AK; Perkins AV; Chess-Williams R; McDermott CM; Forbes A; Christie D; Anoopkumar-Dukie S
Naunyn Schmiedebergs Arch Pharmacol; 2015 Jul; 388(7):793-9. PubMed ID: 25708950
[TBL] [Abstract][Full Text] [Related]
17. Apogossypolone, a novel inhibitor of antiapoptotic Bcl-2 family proteins, induces autophagy of PC-3 and LNCaP prostate cancer cells in vitro.
Zhang XQ; Huang XF; Hu XB; Zhan YH; An QX; Yang SM; Xia AJ; Yi J; Chen R; Mu SJ; Wu DC
Asian J Androl; 2010 Sep; 12(5):697-708. PubMed ID: 20657602
[TBL] [Abstract][Full Text] [Related]
18. Apalutamide: A new agent in the management of prostate cancer.
May MB; Glode AE
J Oncol Pharm Pract; 2019 Dec; 25(8):1968-1978. PubMed ID: 31359832
[TBL] [Abstract][Full Text] [Related]
19. Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291.
Kawata H; Arai S; Nakagawa T; Ishikura N; Nishimoto A; Yoshino H; Shiraishi T; Tachibana K; Nakamura R; Sato H
Prostate; 2011 Sep; 71(12):1344-56. PubMed ID: 21308717
[TBL] [Abstract][Full Text] [Related]
20. Justicidin A-induced autophagy flux enhances apoptosis of human colorectal cancer cells via class III PI3K and Atg5 pathway.
Won SJ; Yen CH; Liu HS; Wu SY; Lan SH; Jiang-Shieh YF; Lin CN; Su CL
J Cell Physiol; 2015 Apr; 230(4):930-46. PubMed ID: 25216025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
